Overview

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if low-dose imatinib and nilotinib combination, will improve treatment results in CML patients with failure, suboptimal response or intolerance to imatinib therapy. The hypothesis is that with low-dose imatinib and nilotinib combination, major molecular response will be achieved in patients not previously obtained with imatinib monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Hospital Universitario Dr. Jose E. Gonzalez

Collaborator:

Novartis Pharmaceuticals

Treatments:

Imatinib Mesylate